Abstract
A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.
| Original language | English |
|---|---|
| Pages (from-to) | 4648-4655 |
| Number of pages | 8 |
| Journal | ACS Applied Bio Materials |
| Volume | 2 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2019 Oct 21 |
Fingerprint
Keywords
- antitumor
- drug targeting
- hypoxia
- prodrug
- theranostic
ASJC Scopus subject areas
- Biomaterials
- Chemistry(all)
- Biomedical Engineering
- Biochemistry, medical
Cite this
Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors. / Koo, Seyoung; Bobba, Kondapa Naidu; Cho, Mi Young; Park, Hye Sun; Won, Miae; Velusamy, Nithya; Hong, Kwan Soo; Bhuniya, Sankarprasad; Kim, Jong Seung.
In: ACS Applied Bio Materials, Vol. 2, No. 10, 21.10.2019, p. 4648-4655.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors
AU - Koo, Seyoung
AU - Bobba, Kondapa Naidu
AU - Cho, Mi Young
AU - Park, Hye Sun
AU - Won, Miae
AU - Velusamy, Nithya
AU - Hong, Kwan Soo
AU - Bhuniya, Sankarprasad
AU - Kim, Jong Seung
PY - 2019/10/21
Y1 - 2019/10/21
N2 - A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.
AB - A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.
KW - antitumor
KW - drug targeting
KW - hypoxia
KW - prodrug
KW - theranostic
UR - http://www.scopus.com/inward/record.url?scp=85073170478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073170478&partnerID=8YFLogxK
U2 - 10.1021/acsabm.9b00722
DO - 10.1021/acsabm.9b00722
M3 - Article
AN - SCOPUS:85073170478
VL - 2
SP - 4648
EP - 4655
JO - ACS Applied Bio Materials
JF - ACS Applied Bio Materials
SN - 2576-6422
IS - 10
ER -